For research use only. Not for therapeutic Use.
Lalistat 2 is an inhibitor of many lipases especially Lysosomal acid lipase (LAL, IC50 = 152 nM), which is a key enzyme that degrades neutral lipids at an acidic pH in lysosomes. Lalistat 2 is commonly used to investigate the cell-specific functions of LAL and LAL deficiency in vitro, as well as specifically measure LAL activity in human blood samples or cells [1][2][3].
Lalistat 2 (30 μM, 7 d) does not affect differentiation of mice adipocytes but reduces isoproterenol-stimulated lipolysis[1].
Lalistat 2 (30 μM, 7 d) inhibits neutral lipid hydrolase activity in mice adipocytes[1].
Lalistat 2 (0.1-100 μM, 20 h) inhibits neutral lipid hydrolases in bone marrow-derived macrophages (BMDM) in a dose-dependent manner[1].
Lalistat 2 (30 μM, 24 h) inhibits adipose triglyceride lipase and hormone-sensitive lipase in mouse and human COS-7 cells[1].
Lalistat 2 (30 μM, 20 h) decreases activities of LAL， ATGL， HSL， MGL， PNPLA6 and NCEH1 in mice bone marrow-derived macrophages[1].
| Catalog Number | I044111 |
| CAS Number | 1234569-09-5 |
| Synonyms | (4-piperidin-1-yl-1,2,5-thiadiazol-3-yl) piperidine-1-carboxylate |
| Molecular Formula | C13H20N4O2S |
| Purity | ≥95% |
| InChI | InChI=1S/C13H20N4O2S/c18-13(17-9-5-2-6-10-17)19-12-11(14-20-15-12)16-7-3-1-4-8-16/h1-10H2 |
| InChIKey | PNYYVHOTXOEBEV-UHFFFAOYSA-N |
| SMILES | C1CCN(CC1)C2=NSN=C2OC(=O)N3CCCCC3 |
| Reference | [1]. Bradić I, et al. Off-target effects of the lysosomal acid lipase inhibitors Lalistat-1 and Lalistat-2 on neutral lipid hydrolases. Mol Metab. 2022，61，101519. [2]. Rosenbaum AI, et al. Thiadiazole carbamates: potent inhibitors of lysosomal acid lipase and potential Niemann-Pick type C disease therapeutics. J Med Chem. 2010, 53(14):5281-9. [3]. Lukacs Z, et al. Best practice in the measurement and interpretation of lysosomal acid lipase in dried blood spots using the inhibitor Lalistat 2. Clin Chim Acta. 2017;471:201-205. |
